2. Academic Validation
  3. Danqi Pill (DQP) Attenuates OGD-Induced Injury in HUVECs via SHP2-ROS-NLRP3 Axis

Danqi Pill (DQP) Attenuates OGD-Induced Injury in HUVECs via SHP2-ROS-NLRP3 Axis

  • Phytochem Anal. 2026 Jan 20. doi: 10.1002/pca.70047.
Xinyi Zhong 1,  Hui Wang 1,  Nan Li 1,  Mijia Zhou 1,  Hanyan Xie 1,  Binghua Tang 1,  Tian Tian 2,  Tianhua Liu 2,  Dongqing Guo 1
Affiliations

Affiliations

  • 1 School of Life Sciences, Beijing University of Chinese Medicine, Beijing, China.
  • 2 School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
PMID: 41559525 DOI: 10.1002/pca.70047
Abstract

Background: The NLRP3 inflammasome-mediated inflammatory response plays a critical role in endothelial dysfunction. Danqi pill (DQP), a Chinese patent medicine composed of Salvia miltiorrhiza and Panax notoginseng, has demonstrated protective effects on endothelial cells, though its underlying mechanisms remain incompletely understood.

Methods: Human umbilical vein endothelial cells (HUVECs) were subjected to oxygen-glucose deprivation (OGD) to simulate ischemic injury. Cell viability, migration, Reactive Oxygen Species (ROS) production, mitochondrial membrane potential, and protein expression related to the NLRP3 inflammasome and Src homology 2-containing protein tyrosine Phosphatase 2 (SHP2) were assessed.

Results: DQP (600 μg/mL) protected HUVECs against OGD-induced injury by enhancing cell viability and migration, reducing ROS production and cell death, and preserving mitochondrial membrane potential. Mechanistically, DQP promoted the translocation of SHP2 to mitochondria, which subsequently suppressed ROS generation and NLRP3 inflammasome activation.

Conclusion: These findings reveal that DQP attenuates OGD-induced injury in HUVECs via SHP2-ROS-NLRP3 axis.

Keywords

Danqi pill (DQP); HUVECs; OGD‐induced injury; SHP2‐ROS‐NLRP3.

Figures
Products